{"entity":{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","aka":[],"tldr":"An Italian nuclear medicine professor who built one of Europe's busiest PET centres in Bologna and co-writes the international guidelines that tell doctors when and how to use PSMA PET scans in prostate cancer.","summary":"Stefano Fanti has directed the Nuclear Medicine Division and PET Unit at the Policlinico Sant'Orsola in Bologna since the early 2000s, building it into one of the most active European centres for non-FDG PET tracers, and is now also Vice Rector for Research at the University of Bologna. He co-authored the first standardised interpretive framework for PSMA-ligand PET (2017) and is a repeat co-author of the EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines that define the clinical role of PSMA PET in staging and restaging.\n\nHe has proposed and co-authored consensus criteria for assessing PSMA PET response to systemic therapy (the PSMA PET progression criteria, and consensus statements on PSMA PET/CT response assessment), and is a co-author of the EANM/SNMMI PSMA PET/CT procedure guideline versions 1.0 and 2.0. His work bridges the clinical and regulatory sides of PSMA imaging standardisation across Europe and the US.","asOf":"2026-09-22","links":[{"label":"University of Bologna profile","url":"https://www.unibo.it/sitoweb/s.fanti/en"},{"label":"Consensus statements on PSMA PET/CT response, EJNMMI 2021","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7835167/"}],"tags":["PSMA","guidelines","clinician"],"related":["psma-pet","ga68-psma-11","sant-orsola-bologna"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Full Professor of Diagnostic Imaging and Director of Nuclear Medicine, University of Bologna / Policlinico Sant'Orsola; Vice Rector for Research, University of Bologna","institutionId":"sant-orsola-bologna","specialisms":["PSMA PET","PET response criteria","guideline development"],"profiles":[{"label":"University of Bologna staff page","url":"https://www.unibo.it/sitoweb/s.fanti/en"},{"label":"University of Bologna CV (English)","url":"https://www.unibo.it/sitoweb/s.fanti/cv-en"},{"label":"Google Scholar","url":"https://scholar.google.com/citations?user=ZB07UFEAAAAJ&hl=en"}],"papers":[{"title":"Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2021,"doi":"10.1007/s00259-020-04934-4"},{"title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria","journal":"Journal of Nuclear Medicine","year":2020,"doi":"10.2967/jnumed.119.233817"},{"title":"PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06089-w"}]},"route":"/people/stefano-fanti/","neighbours":{"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"drug":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"}],"institution":[{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/"}]}}